Meningitis Vaccination Advances

There has been significant progress on a low cost vaccination against Neisseria meningitidis, one of two strains of bacteria that cause the majority of Africa's meningitis caseload. Phase III clinical trials conducted in the Gambia, Senegal and Mali have shown positive results, and it is expected that the vaccine can be introduced from

To read the full article, please choose one of the following options: